Anti-PD-L1 [mAb #18 (PD-L1.A)]

Absolute Antibody

Anti-PD-L1 [mAb #18 (PD-L1.A)]

7

The antibody could significantly inhibit the binding of PD-1 and PD-L1 at the cellular level. The humanized version of the antibody was constructed. The humanized version of the antibody detected the PD-L1 by western blot analysis. The binding affinity of the mouse and humanized version of the antibody to PD-L1 was measured by surface plasmon resonance, the affinity was respectively 8.81 nM 7.77 nM. In vivo studies demonstrated that the humanized version of the antibody could effectively inhibit tumour growth showing potential tumour therapeutic value (CN109232740). This antibody was also used in the generation of a bispecific antibody (BsAb) in a dual-variable-domain immunoglobulin (DVD-Ig) format targeting CD47 and PD-L1. The variable-domain from the PD-L1-blocking mAb #18 was introduced in tandem onto h4C1 to generate a dual variable domain bsAb that binds bivalently to both CD47 and PD-L1. This BsAb retained blocking activity for both interactions, but lacked the hemagglutinating activity of the parental m4C1 (Shi et al.; 2020; PMID: 32296041; Kaur et al.; 2020; PMID: 33244513).

Western Blot, Neutralisation/Blocking, Other Application

Inhibition; SPR; WB; in vivo

Research Use Only

Monoclonal

mAb #18 (PD-L1.A)

CD274

CD274 molecule

B7 homolog 1; B7-H; B7H1; CD274 antigen; hPD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; PD-L1; programmed cell death 1 ligand 1

Mouse

IgG1

Programmed cell death 1 ligand 1

This chimeric mouse antibody was made using the variable domain sequences of the original format for improved compatibility with existing reagents assays and techniques.

Human

The original antibody was generated by immunizing BALB/c mice with PD-L1.

-20°C,2°C to 8°C

12352203